CGTN
China is mulling improving the electoral system of the Hong Kong Special Administrative Region (HKSAR) – but critics say it's a plan to eliminate opposition forces in the city.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210308005793/en/
Why are improvements imperative?
When explaining the draft decision on improving the electoral system of the HKSAR to lawmakers, Wang Chen, vice chairman of the National People's Congress (NPC) Standing Committee, said the move is to prevent anti-China, destabilizing forces from seizing power, citing the months-long riots in 2019.
"To remedy the situation, it is important to take necessary steps to improve the electoral system and remove existing institutional deficiencies and risks to ensure the administration of Hong Kong by Hong Kong people with patriots as the main body," Wang said.
Alex Fan, founding president of the International Youth Legal Exchange Federation in Hong Kong, told CGTN that "allowing non-patriots or even people endangering national security to participate in the election will put the 'One Country, Two Systems' in peril."
What can be improved?
According to the draft decision, the focus of the improvements will be on the reform and greater empowerment of the city's Election Committee.
"Hong Kong's chief executive will continue to be elected by the Election Committee. The committee will also elect a relatively large share of Legislative Council (LegCo) members and directly participate in the nomination of all LegCo candidates," Wang said, adding that the revisions to be made may be limited to Annex I and Annex II to the Basic Law, without revising the main body of the Basic Law.
How will it be carried out?
A two-step approach, namely, "decision plus amendment," has been put forward. The NPC, China's top legislature, first makes a decision on improving the electoral system of the HKSAR and authorizes its Standing Committee to amend. Then the NPC Standing Committee amends the Annex I and Annex II to the Basic Law of the HKSAR.
After the amendment at the state level is completed, the HKSAR will amend relevant local laws accordingly.
In consideration of the complexity of Hong Kong's election-related local laws, experts believe the process will take some time but will be completed before elections in Hong Kong in the second half of the year.
What would the improvements mean?
Li Huan, an associate research fellow at the Hong Kong and Macao Research Center, rejected concerns that the non-establishment camp in Hong Kong would have no room to participate in politics after the amendment, saying the decision "does not aim to serve the pro-establishment camp or to restrict the non-establishment camp."
"It depends on how one understands the non-establishment camp. People from the non-establishment camp are not necessarily unpatriotic or those who don't love Hong Kong," Li told CGTN.
This echoed the words of Xia Baolong, vice chairman of the National Committee of the Chinese People's Political Consultative Conference and head of the Hong Kong and Macao Affairs Office of the State Council, who has said the emphasis on "patriots governing Hong Kong" is not meant to erase all differences.
Liu Zhaojia, the vice chairman of the National Hong Kong and Macao Research Association, added: "Pro-establishment candidates can also rest easy. They must put in real efforts to solve Hong Kong's social and livelihood problems in order to gain a better political future."
The Liaison Office of the HKSAR voiced support for improving the electoral system, stating "it is the only way for Hong Kong society to end political disputes, refocus on development and protect the long-term prosperity and stability."
The HKSAR delegation to the Two Sessions said the proposed improvements would not make any change to "One Country, Two Systems," but would strengthen the principle, as well as put an end to the political chaos in Hong Kong and allow local society to focus on economic development, people's livelihood and the SAR's integration into the overall development of the country.
No one cares more about Hong Kong's democracy and continued prosperity and stability than the Central Government of China, Chinese State Councilor and Foreign Minister Wang Yi stated on Sunday, adding that Hong Kong's shift from chaos to stability serves the interests of all parties.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210308005793/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MSCI Announces Baer Pettit to Retire as President17.11.2025 13:00:00 CET | Press release
Additional senior leadership changes will drive growth in new client segments and products MSCI Inc. (NYSE: MSCI), a leading provider of critical decision support tools and services for the global investment community, announced that C.D. Baer Pettit, President and Chief Operating Officer (COO), and a member of the Board of Directors, has informed the company that he will retire next year after more than 25 years in senior leadership roles. Mr. Pettit will continue to serve as President and a Director until March 1, 2026, and will remain as an advisor to the company for a period of time to ensure a smooth transition. Mr. Pettit joined MSCI in 2000 and has served in numerous senior leadership roles, including heading Client Coverage, Marketing and Index. He was appointed COO in 2015 and President in 2017, overseeing all products and operations, and he joined the Board of Directors in 2023. “Baer has been my longtime business partner, and he has played a pivotal role in shaping MSCI’s st
AdvanCell Appoints Philina Lee, PhD as Chief Executive Officer to Lead US Expansion and Drive Global Growth17.11.2025 13:00:00 CET | Press release
Dr Lee is a seasoned biopharmaceutical executive with a proven track record of leading cross-functional teams to successfully develop and commercialize innovative therapies in oncology AdvanCell Pty Ltd (“AdvanCell”), a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced the appointment of Philina Lee, PhD as Chief Executive Officer and member of the Board of Directors. Dr Lee will head AdvanCell’s US expansion, accelerating clinical, manufacturing, and partnership activities to advance lead clinical candidate 212Pb-ADVC001 and the company’s innovative radiopharmaceutical portfolio. She will assume her role from January 1, 2026, and will be based at the company’s new US headquarters near Boston/Cambridge, MA. “Philina brings a rare combination of global commercial leadership, deep radiopharmaceutical expertise, and an outstanding record of building high growth organizations and high-performance teams,” said Andrew Kay, C
Connections, Local Flavors, and Luxurious Experiences Top the 2026 Bacardi Cocktail Trends Report17.11.2025 13:00:00 CET | Press release
This year’s findings highlight a move towards more meaningful occasions, micro-indulgence, and storytelling cocktail experiences The five defining trends set to reshape cocktail culture and the spirits industry in 2026 are highlighted in the seventh annual Bacardi Cocktail Trends Report. The Report released by Bacardi Limited, the largest privately held international spirits company, in partnership with The Future Laboratory (TFL), draws on data from Bacardi-led and third-party research, consumer surveys, bartender interviews and TFL’s trend forecasting to uncover the forces shaping cocktail experiences, flavor innovation, and drinking culture in the year ahead. The Report also reveals the cocktails which are set to be the most popular in 2026 and trends for younger Legal Drinking Age (LDA) consumers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117678098/en/ The 7th annual Bacardi Cocktail Trends Report unveils what an
Arada to Acquire Majority Stake in £2.5bn Thameside West Development, Unlocking One of London’s Largest and Most Connected New Waterfront Neighbourhoods17.11.2025 12:58:00 CET | Press release
Arada, the UAE’s fastest-growing master developer, announces that it has agreed the acquisition of an 80% stake in Thameside West, a landmark waterfront mixed-use development located at the western end of London’s Royal Docks. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117374964/en/ HH Sheikh Sultan bin Ahmed Al Qasimi, Chairman of Arada (centre) with members of the Arada and Keystone executive teams (Photo: AETOSWire) Master-planned by Foster + Partners, the vibrant new urban destination will deliver at least 5,000 homes, with half of the site dedicated to green space and a kilometre of active waterfront. Boasting unrivalled transport links, the integration of air, road, rail, river and tunnel links makes this one of the most connected sites in London. Spread over a 47-acre area – twice the size of the Hudson Yards mixed-use development in New York - Thameside West represents one of Europe’s largest and most strategi
Positive Phase 3 Results Support ZIIHERA® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma17.11.2025 12:00:00 CET | Press release
ZIIHERAplus TEVIMBRA and chemotherapy demonstrated clinically meaningful and statistically significant improvements in PFS and OS versus trastuzumab and chemotherapyZIIHERA plus chemotherapy showed a clinically meaningful and statistically significant improvement in PFS versus trastuzumab and chemotherapy, and a clinically meaningful effect with a strong trend toward statistical significance for OS at the first interim analysisFirst Phase 3 trial in 15 years to demonstrate a clinical benefit in this patient population with a novel HER2-targeted therapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive top-line results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with or without PD-1 inhibitor TEVIMBRA® (tislelizumab), as first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
